This review concluded that several drugs were shown to improve walking distance in people with intermittent claudication, but with limited benefits. Overall the authors' conclusions were supported by the results, but they should be interpreted with some caution due to the possibility of publication bias, a lack of information on study quality and differences between studies.
Treadmill tests were used to evaluate walking with protocols that involved either constant or graded loads (most were 3km/h). Specific interventions assessed by the included studies were: anti-platelet agents (ticlopidine, cloricromene, mesoglycan, indobufen, defibrotide); lipid lowering agents (atorvastatin, simvastatin, policosanol,avasimibe); phosphodiesterase inhibitors (cilostazol, pentoxifylline, phosphodiesterase inhibitor); prostaglandins (prostoglandin, iloprost); proteoglycans (heparan sulfate,calcium-heparin, sulodexide, L-arginine); vasodilators (naftidrofuryl, inositol nicotinate); calcium chelators (EDTA); CNS-stimulators (hydroxytryptamine); propionul-L-carnitine; and prostacyclin. Duration of follow-up ranged from 0 to 18 months.
Two reviewers independently assessed studies for inclusion.
Assessment of study quality
One reviewer assessed blinding procedures at treatment and outcome assessment, quality of randomisation, allocation concealment, description of drop-outs and withdrawals, intention-to-treat (ITT) analysis, presence of power calculation and adequate description of statistical methods. Results were double checked by a second reviewer.
Data extraction
One reviewer extracted data as means and standard deviations (SD) for maximal walking distance, where possible. Data were extracted on an ITT basis.
Methods of synthesis
Weighted mean differences (WMD) together with 95% confidence intervals (CI) were estimated for maximal walking distance using random-effects models. Results were stratified on intervention grouping. Studies had to report mean and standard deviation for maximal walking distance to be included in the meta-analysis. Heterogeneity was assessed using the Χ 2 test. Forty three RCTs were included (n=11,686) in the review; 26 provided sufficient information for inclusion in the metaanalysis.
Results of the review
Significant beneficial effects on maximal walking distance were reported for: anti-platelet agents (WMD 59m, 95% CI 37m to 81m; five RCTs); lipid-lowering agents (WMD 163m, 95% CI 83m to 242m; five RCTs); phosphodiesterase inhibitors (WMD 49m, 95% CI 37m to 61m; 12 RCTs); prostaglandins (WMD 66m, 95% CI 5m to 128m; four RCTs); and prosteoglycans (WMD 57m, 95% CI 16m to 97m; three RCTs).
There was no difference in WMD for maximal walking distance for vasodilators (five RCTS) as a whole compared to placebo. However, the four studies that evaluated naftidrofuryl reported significant beneficial effects (WMD 90, 95% CI 14m to 167m).
There was strong evidence of statistical heterogeneity for all meta-analyses except that of antiplatelet agents.
Authors' conclusions
Several drugs have been shown to improve maximal walking distance, but with limited benefits. Statins seem to be the most efficient drug available at the time of the review.
CRD commentary
The review addressed a focused question supported by clearly defined inclusion criteria. An appropriate literature search was conducted for published studies, but restriction of the review to published peer-reviewed studies raised the possibility of publication bias. Appropriate steps were taken to minimise bias and errors in the selection of studies with some attempts for quality assessment, but data extraction was carried out only by a single reviewer. Study quality was assessed with appropriate criteria, but the results were not presented. Methods used to pool studies were appropriate, but there was substantial heterogeneity between studies and this was not investigated further. Overall the authors' conclusions were supported by the results, but they should be interpreted with some caution due to the possibility of publication bias, a lack of information on study quality and differences between studies.
Implications of the review for practice and research
Practice: The authors did not state any implications for practice.
Research: The authors stated that there was a need for strict trials on exercise therapy for intermittent claudication that should also examine issues of cost and QoL. There was also a question of whether particular drugs had synergistic interactions with exercise and smoking cessation and how to educate patients to take responsibility in their own smoking cessation and rehabilitation with exercise.
